Japan records surprise trade deficit in July as exports weaken further
Investing.com - Benchmark has reiterated a Buy rating and $30.00 price target on IMAX Corporation (NYSE:IMAX) amid reports of potential premium format competition from major theater chains. The stock, currently trading at $28.61, has delivered an impressive 61.79% return over the past year and is approaching its 52-week high of $29.66. According to InvestingPro data, IMAX maintains strong financial health with liquid assets exceeding short-term obligations.
The research firm views rumors that some theater chains may be considering a joint premium large format (PLF) brand as validation of IMAX’s growing influence rather than a near-term competitive threat.
Reports suggest Cinemark, Regal, and Marcus are exploring a collaborative PLF strategy, though none of these companies have made public comments on the matter.
Benchmark notes these circuits already operate their own premium formats (XD, RPX, MT-X), which have historically coexisted with IMAX without challenging its brand equity, filmmaker relationships, or box office performance.
Despite representing approximately 1% of screens, IMAX regularly delivers over 10 percent of blockbuster grosses and is on track for a record box office year in 2025, according to the research firm.
In other recent news, IMAX Corporation reported significant developments across various areas. The company announced an agreement with HOYTS Cinemas to open up to five new theaters in Australia, utilizing IMAX with Laser systems. This expansion aims to capitalize on Australia’s strong market performance, where IMAX’s share of the box office has grown significantly. Additionally, IMAX has expanded its credit facility to $375 million, with the potential to increase it to $515 million, providing financial flexibility for future operations and growth. In the realm of film releases, Warner Bros./DC Studios’ "Superman" generated $30.4 million globally in IMAX theaters during its opening weekend, marking a record market share for IMAX in North America. Benchmark maintained its Buy rating on IMAX, citing the company’s robust Q2 box office performance and its strategic position in premium cinema. Furthermore, IMAX expanded its share repurchase program by $100 million, bringing the total authorization to $500 million, with $250 million still available. These recent developments reflect IMAX’s strategic efforts to enhance its market presence and financial stability.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.